Measuring the Impact of a Mobile Health System to Support Healthy Pregnancies and Improve Newborn Survival (mCARE-II)

mCARE II: Enhancing, Integrating and Scaling mCARE and Measuring the Impact of a Mobile Health System to Support Healthy Pregnancies and Improve Newborn Survival

The purpose of this community-based randomized controlled trial is to test whether the mCARE-II intervention package, delivered by the existing Government of Bangladesh community health workforce, will improve neonatal and perinatal survival in a rural setting in northwestern Bangladesh. mCARE-II is a digital health intervention, which incorporates automated workload scheduling, client prioritization and risk stratification, overdue service reminders and demand generation through client side reminder messaging. The intervention package focuses on the pregnancy and early postpartum period.

Study Overview

Detailed Description

The aim of this study is to implement and evaluate the mCARE-II intervention package using a randomized controlled trial design. This package, supported by an mHealth application, provides workflow scheduling for guided household registration, census, pregnancy surveillance, and antenatal, postnatal, and essential newborn care visit reminders. Workflow scheduling is sorted and prioritized based on assessment of basic risk. Furthermore, the system integrates client-directed reminder SMS messages and demand-side birth notifications to schedule postnatal services immediately after birth. This will be operated by the Government of Bangladesh (GoB) community health workers, called Family Welfare Assistants (FWAs), in 18 unions of one northern district of Bangladesh who will use the system to support their routine health service delivery functions. Based on lessons learned from phase I implementation under the pilot study, additional features will be added to the intervention package, including a priority sorting algorithm to identify pregnant women and newborns with known risk factors for adverse outcomes to prioritize them for scheduled visits, a birth preparedness module to help pregnant women and their families plan for safe delivery and childbirth, and targeted newborn care counseling during late antenatal encounters. These features will be built on a scalable platform compatible with national data systems and aligned with a new global standard being advocated by WHO - the Open Smart Register Platform or OpenSRP (smartregister.org).

Based on randomization to mCARE-II or control arms by FWA catchment area, participants living in each area will receive services from their FWA, either supported by OpenSRP or according to the standard of care procedures currently in place. Performance of the FWAs and the health status of enrolled women and newborns will be monitored and evaluated by a rigorous research layer supported by a cadre of research workers who will verify services received by participants to assess exposure to and interactions with FWAs and OpenSRP. This study combines a robust RCT methodology with principles of implementation science - actual government health workers using OpenSRP to support their routine work while a cadre of highly-trained research workers collects 'gold-standard' denominator data against which to measure performance. This study is an effort to rigorously evaluate the set of mCARE-II interventions on the OpenSRP platform.

Study Type

Interventional

Enrollment (Actual)

113539

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Gaibandha, Bangladesh, 5700
        • JiVitA: Maternal and Child & Nutrition Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 45 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Married women of reproductive age living with their husbands in the JiVitA study area in Gaibandha, Bangladesh
  • Consented for participation in 8 weekly pregnancy surveillance
  • Self reported as being pregnant
  • Infants born to eligible, enrolled women

Exclusion Criteria:

  • Women who are menopausal or sterilized
  • Refused to participate in 8 weekly pregnancy surveillance

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: mCARE-II
mCARE-II supported service provision through existing community health workforce.
mCARE-II is a package of interventions that provides guided client enumeration and follow-up support to community health workers, automated workflow scheduling, risk assessment, client prioritization and stratification and client-based demand generation messaging. These features are incorporated into a platform called OpenSRP, which integrates text message reminders, scheduling, and form submissions on the server side, and displays schedules and client lists on a tablet-based application for community health workers.
No Intervention: Comparison
Standard of care, paper-based service provision through existing community health workforce.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Decrease in Neonatal Mortality
Time Frame: Within 43 days after birth
Within 43 days after birth
Decrease in perinatal mortality
Time Frame: 22 Weeks Gestation through the first 7 days after birth
22 Weeks Gestation through the first 7 days after birth

Secondary Outcome Measures

Outcome Measure
Time Frame
Increase in postnatal care utilization
Time Frame: Within 7 days of delivery/child birth
Within 7 days of delivery/child birth
Increase in essential newborn care utilization
Time Frame: Within 7 days of delivery/child birth
Within 7 days of delivery/child birth
Increase in antenatal care utilization
Time Frame: up to 34 weeks of pregnancy
up to 34 weeks of pregnancy
Increase in skilled birth attendance
Time Frame: During child birth
During child birth
Increase in immediate breastfeeding
Time Frame: Within first hour of life
Within first hour of life
Increase in facility-based delivery
Time Frame: At time of delivery
At time of delivery
Increase in skilled birth attendance
Time Frame: At time of delivery
At time of delivery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2016

Primary Completion (Actual)

December 22, 2020

Study Completion (Actual)

December 22, 2020

Study Registration Dates

First Submitted

September 19, 2016

First Submitted That Met QC Criteria

September 20, 2016

First Posted (Estimated)

September 21, 2016

Study Record Updates

Last Update Posted (Actual)

July 17, 2023

Last Update Submitted That Met QC Criteria

July 13, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe